|
US4197307A
(en)
|
1977-04-12 |
1980-04-08 |
Ciba-Geigy Corporation |
2-Alkylthio-, 2-alkylsulphinyl- and 2-alkylsulfonyl-6-phenylbenzimidazoles as anthelmintic agents
|
|
EP0377903A3
(de)
|
1989-01-09 |
1991-07-17 |
Bayer Ag |
Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung
|
|
US6787652B1
(en)
|
1999-09-30 |
2004-09-07 |
Pfizer, Inc. |
6-Azauracil derivatives as thyroid receptor ligands
|
|
DE60020786T2
(de)
|
1999-09-30 |
2006-03-23 |
Pfizer Products Inc., Groton |
6-Azauracilderivate als Liganden der Thyroidrezeptoren
|
|
GB0015205D0
(en)
|
2000-06-21 |
2000-08-09 |
Karobio Ab |
Bioisosteric thyroid receptor ligands and method
|
|
WO2002051805A1
(de)
|
2000-12-27 |
2002-07-04 |
Bayer Aktiengesellschaft |
Indol-derivate
|
|
EP1471049A4
(en)
|
2002-01-30 |
2006-08-16 |
Kissei Pharmaceutical |
NEW THYROIDIAN HORMONE RECEPTOR LIGAND, MEDICINAL PREPARATIONS CONTAINING THE SAME AND USE THEREOF
|
|
WO2003094845A2
(en)
|
2002-05-08 |
2003-11-20 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
|
GB0327319D0
(en)
|
2003-11-24 |
2003-12-24 |
Pfizer Ltd |
Novel pharmaceuticals
|
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
|
FR2882750B1
(fr)
|
2005-03-03 |
2007-05-11 |
Pierre Fabre Medicament Sa |
Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
|
|
GB0513692D0
(en)
|
2005-07-04 |
2005-08-10 |
Karobio Ab |
Novel pharmaceutical compositions
|
|
CA2614529C
(en)
*
|
2005-07-21 |
2011-06-28 |
F. Hoffmann-La Roche Ag |
Pyridazinone derivatives as thyroid hormone receptor agonists
|
|
GB0608724D0
(en)
|
2006-05-03 |
2006-06-14 |
Karobio Ab |
Novel Pharmaceutical Compositions
|
|
GB0610322D0
(en)
|
2006-05-24 |
2006-07-05 |
Karobio Ab |
Novel pharmaceutical compositions
|
|
US8394811B2
(en)
|
2007-04-18 |
2013-03-12 |
Molsoft Llc |
Hydrazide compounds as thyroid hormone receptor modulators and uses thereof
|
|
HRP20140522T1
(hr)
|
2007-06-27 |
2014-08-15 |
Quark Pharmaceuticals, Inc. |
Pripravci i metode za inhibiranje izražaja proapoptotiäśkih gena
|
|
TW200906823A
(en)
|
2007-07-16 |
2009-02-16 |
Lilly Co Eli |
Compounds and methods for modulating FXR
|
|
US8076334B2
(en)
|
2007-09-20 |
2011-12-13 |
Hoffmann-La Roche Inc. |
Prodrugs of thyroid hormone analogs
|
|
FR2933979B1
(fr)
|
2008-07-15 |
2012-08-24 |
Pf Medicament |
Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
|
|
AU2010240200B2
(en)
|
2009-04-20 |
2014-03-13 |
Mitsubishi Tanabe Pharma Corporation |
Novel thyroid hormone beta receptor agonist
|
|
WO2011038207A1
(en)
|
2009-09-25 |
2011-03-31 |
Metabasis Therapeutics, Inc. |
Phosphorus-containing thyroid hormone receptor agonists and methods of use
|
|
AU2012339640B2
(en)
|
2011-11-14 |
2017-01-05 |
Ignyta, Inc. |
Uracil derivatives as AXL and c-MET kinase inhibitors
|
|
CN103130723B
(zh)
*
|
2011-11-30 |
2015-01-14 |
成都地奥制药集团有限公司 |
一种多聚(adp-核糖)聚合酶抑制剂
|
|
CN102898377B
(zh)
|
2012-02-14 |
2016-01-20 |
南京圣和药业股份有限公司 |
一类酞嗪酮衍生物及其用途
|
|
EP4023641B1
(en)
|
2012-09-17 |
2024-05-01 |
Madrigal Pharmaceuticals, Inc. |
Method of synthesizing thyroid hormone analogs and polymorphs thereof
|
|
UA121208C2
(uk)
|
2014-04-11 |
2020-04-27 |
Сімабей Терапьютікс, Інк. |
Лікування нажхп та насг
|
|
JP6814730B2
(ja)
|
2014-09-05 |
2021-01-20 |
ジェネンテック， インコーポレイテッド |
治療用化合物およびその使用
|
|
CN105477636B
(zh)
|
2015-10-16 |
2019-09-17 |
厦门大学 |
使用阿维菌素及其衍生物治疗代谢疾病的方法
|
|
TWI757266B
(zh)
|
2016-01-29 |
2022-03-11 |
美商維它藥物有限責任公司 |
ＲＯＲ－γ調節劑
|
|
WO2017170434A1
(ja)
|
2016-03-28 |
2017-10-05 |
大日本住友製薬株式会社 |
Ｆｘｒアゴニストとａｒｂの組み合わせ医薬
|
|
CN114796237B
(zh)
|
2016-03-31 |
2024-02-23 |
基恩菲特公司 |
胆汁淤积性疾病的治疗方法
|
|
KR20190040936A
(ko)
|
2016-05-25 |
2019-04-19 |
아카나 테라퓨틱스, 엘티디. |
파르네소이드 x 수용체 (fxr) 조정제와의 조합 요법
|
|
WO2018027892A1
(en)
|
2016-08-12 |
2018-02-15 |
Eli Lilly And Company |
Amino pyrimidine ssao inhibitors
|
|
ES2924257T3
(es)
|
2016-10-18 |
2022-10-05 |
Madrigal Pharmaceuticals Inc |
Métodos de tratar trastornos hepáticos o trastornos lipídicos con un agonista de THR-beta
|
|
EP3528800A1
(en)
|
2016-10-19 |
2019-08-28 |
Boehringer Ingelheim International GmbH |
Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
|
|
CN108883185B
(zh)
|
2016-12-06 |
2021-10-08 |
江苏恒瑞医药股份有限公司 |
一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途
|
|
AU2018223146B2
(en)
|
2017-02-21 |
2023-12-21 |
Genfit |
Combination of a PPAR agonist with a FXR agonist
|
|
BR112019018162A2
(pt)
|
2017-03-13 |
2020-04-07 |
Genfit |
Composições farmacêuticas para terapia de combinação
|
|
WO2018170173A1
(en)
|
2017-03-15 |
2018-09-20 |
Metacrine, Inc. |
Farnesoid x receptor agonists and uses thereof
|
|
CN110536682B
(zh)
|
2017-04-18 |
2023-01-06 |
基恩菲特公司 |
依拉非诺或其衍生物与抗nash、抗纤维化或抗胆汁淤积药剂的组合
|
|
WO2018208707A1
(en)
|
2017-05-08 |
2018-11-15 |
Neurovia, Inc. |
Methods and compositions for treating demyelinating diseases
|
|
WO2019023245A1
(en)
|
2017-07-25 |
2019-01-31 |
Cedars-Sinai Medical Center |
METHODS OF TREATING HEPATIC DISEASES
|
|
AU2018320715A1
(en)
|
2017-08-25 |
2020-02-13 |
Genfit |
Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
|
|
WO2019053235A1
(en)
|
2017-09-15 |
2019-03-21 |
Genfit |
NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS
|
|
SG11202001111QA
(en)
|
2017-09-18 |
2020-03-30 |
Genfit |
Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
|
|
KR102732404B1
(ko)
|
2017-11-01 |
2024-11-19 |
브리스톨-마이어스 스큅 컴퍼니 |
파르네소이드 x 수용체 조정제로서의 알켄 화합물
|
|
EP3710599B1
(en)
|
2017-11-13 |
2024-07-17 |
Gilead Sciences, Inc. |
Method for staging liver fibrosis in nash patients
|
|
EP3725779A4
(en)
|
2018-01-23 |
2021-02-24 |
Shenzhen TargetRx, Inc. |
SUBSTITUTED PYRIDAZINONE COMPOUND
|
|
AU2019257632A1
(en)
|
2018-04-24 |
2020-11-26 |
Ph Pharma Co., Ltd. |
Use of neutrophil elastase inhibitors in liver disease
|
|
KR102531771B1
(ko)
|
2018-06-12 |
2023-05-11 |
스촨 하이스코 파마수티컬 씨오., 엘티디 |
갑상선 호르몬 수용체 작용제 및 그 용도
|
|
US10800767B2
(en)
|
2018-08-24 |
2020-10-13 |
Terns, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
EP3844156A4
(en)
|
2018-08-30 |
2022-06-08 |
Terns Pharmaceuticals, Inc. |
TREATMENT OF HEPATIC DISORDERS
|
|
PE20211644A1
(es)
|
2018-09-18 |
2021-08-24 |
Terns Inc |
Compuestos para tratar ciertas leucemias
|
|
JP2022500396A
(ja)
|
2018-09-18 |
2022-01-04 |
メタクリン，インク． |
疾患の処置用のファルネソイドｘ受容体アゴニスト
|
|
KR20210076932A
(ko)
|
2018-10-12 |
2021-06-24 |
인벤티스바이오 컴퍼니 리미티드 |
갑상선 호르몬 수용체 작용제
|
|
TWI884745B
(zh)
|
2018-10-12 |
2025-05-21 |
美商拓臻股份有限公司 |
甲狀腺素受體β促效劑化合物
|
|
CN121081472A
(zh)
|
2018-12-13 |
2025-12-09 |
拓臻股份有限公司 |
一种THRβ受体激动剂化合物及其制备方法和用途
|
|
US11833167B2
(en)
|
2018-12-17 |
2023-12-05 |
Mitopower Llc |
Nicotinyl riboside compounds and their uses
|
|
CN111484481A
(zh)
|
2019-01-26 |
2020-08-04 |
察略盛医药科技(上海)有限公司 |
哒嗪酮类衍生物、其制备方法及其在医药上的用途
|
|
CN119431265A
(zh)
|
2019-02-21 |
2025-02-14 |
南京瑞捷医药科技有限公司 |
一种作为甲状腺激素受体激动剂的化合物
|
|
KR20220017917A
(ko)
|
2019-05-08 |
2022-02-14 |
알리고스 테라퓨틱스 인코포레이티드 |
Thr-베타의 조절제 및 이의 사용 방법
|
|
CN111909137B
(zh)
|
2019-05-10 |
2023-05-30 |
深圳微芯生物科技股份有限公司 |
一种哒嗪酮衍生物及其应用
|
|
CN114174282A
(zh)
|
2019-05-29 |
2022-03-11 |
南京明德新药研发有限公司 |
作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
|
|
CA3142905A1
(en)
|
2019-07-23 |
2021-01-28 |
Novartis Ag |
Combination treatment of liver diseases using fxr agonists
|
|
CN112409340B
(zh)
|
2019-08-21 |
2022-03-18 |
海创药业股份有限公司 |
卤素取代的苯醚类化合物及其用途
|
|
EP4017875A4
(en)
|
2019-08-23 |
2023-05-03 |
Terns Pharmaceuticals, Inc. |
THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS
|
|
AU2020346057A1
(en)
|
2019-09-12 |
2022-04-21 |
Terns Pharmaceuticals, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
TW202128668A
(zh)
|
2019-12-16 |
2021-08-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
并環類衍生物、其製備方法及其在醫藥上的應用
|
|
AU2021273487A1
(en)
|
2020-05-13 |
2023-01-05 |
Terns Pharmaceuticals, Inc. |
Combination treatment of liver disorders
|
|
CA3183414A1
(en)
|
2020-05-13 |
2021-11-18 |
Terns Pharmaceuticals, Inc. |
Combination treatment of liver disorders
|
|
MX2023004257A
(es)
|
2020-10-15 |
2023-05-30 |
Lilly Co Eli |
Polimorfos de un agonista de fxr.
|
|
CN114437034A
(zh)
|
2020-11-06 |
2022-05-06 |
深圳微芯生物科技股份有限公司 |
一种酞嗪类化合物的可药用盐、晶型及其制备方法
|
|
US20240100125A1
(en)
|
2021-01-14 |
2024-03-28 |
Enyo Pharma |
Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
|
|
US20240059682A1
(en)
|
2021-03-03 |
2024-02-22 |
Terns Pharmaceuticals, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
WO2022194278A1
(zh)
|
2021-03-19 |
2022-09-22 |
南京明德新药研发有限公司 |
双环苯酚类化合物及其应用
|
|
CN118871113A
(zh)
|
2021-11-11 |
2024-10-29 |
拓臻制药公司 |
使用THR-β激动剂的肝脏病症的治疗
|
|
EP4429665A1
(en)
|
2021-11-11 |
2024-09-18 |
Terns Pharmaceuticals, Inc. |
Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders
|
|
CA3238102A1
(en)
|
2021-11-11 |
2023-05-19 |
Terns Pharmaceuticals, Inc. |
Treating liver disorders with an ssao inhibitor
|
|
WO2023220404A1
(en)
|
2022-05-13 |
2023-11-16 |
Terns Pharmaceuticals, Inc. |
Treatment of non-alcoholic steatohepatitis
|